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1. Introduction  
A radioiodine whole body scan relies on the fact that differentiated thyroid cancer is more 
efficient at trapping circulating radioiodine than any other tissues.(Hyer, Newbold et al. 
2010) Therefore, when I-131 is administered it accumulates in the thyroid cancer tissues and 
a radioiodine whole body scan plays an important role in the management of patients with 
differentiated thyroid cancer. Uptake of iodine by the cancer is related to the expression of 
sodium iodide symporter (NIS), which actively transports iodide into the cancer cells. 
Extrathyroidal tissues, such as stomach, salivary glands and breast, are known to have the 
NIS expression and the organs can physiologically take up iodine.(Riesco-Eizaguirre and 
Santisteban 2006) 
On a whole body scan with diagnostic or therapeutic doses of I-131, except for the 
physiological radioiodine uptake in the salivary glands, stomach, gastrointestinal and 
urinary tracts, the lesions with radioiodine uptake can be considered as metastatic lesions in 
thyroid cancer patients who previously underwent total thyroidectomy. 
However, a variety of unusual lesions may cause a false positive result on the radioiodine 
whole body scan and so careful evaluation of an abnormal scan is imperative to 
appropriately manage patients with differentiated thyroid cancer.(Mitchell, Pratt et al. 2000; 
Shapiro, Rufini et al. 2000; Carlisle, Lu et al. 2003; Ahn, Lee et al. 2011) The decision to 
administer radioiodine treatment is mainly based on the diagnostic scan, and 
misinterpretation of physiological or other causes of radioiodine uptake as metastatic 
thyroid cancer could lead to the decision to perform unnecessary surgical removal or to 
administer a high dose of I-131, which results in fruitless radiation exposure. Therefore, 
correct interpretation of the diagnostic scan is critical for the proper management.  
Physiologic iodine uptake, pathologic iodine uptakes that are not related to thyroid cancer 
and contamination by physiologic excretion of tracer on the whole body scan are presented 
and discussed in this chapter. The purpose of this chapter is to make readers consider the 
possibility of physiologic or pathologic false positive uptake as a reason for the tracer 
uptake seen on the radioiodine whole body scan. 
2. Iodine and the thyroid gland  
Iodine is an element with a high atomic number 53, it is purple in colour and it is 
represented by the symbol I, and the iodine is an essential component of the hormones  
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Fig. 1. Simplified diagram of the metabolic circuit of iodine. Iodine (I) ingested orally is 
absorbed from the small bowel into the circulating iodine pool. About one fifth of the iodine 
in the pool is removed by the thyroid gland and surplus iodine is rapidly excreted by the 
kidney and bowel. In the thyroid gland, iodine is used to produce thyroid hormones (Hr), 
which act in peripheral tissues. Iodine released from thyroid hormones re-enter into the 
circulating iodine pool.  
produced by the thyroid gland. The thyroid hormones are essential for the health and well-
being for mammals. Iodine comprises about 60% of the weights of thyroid hormones. The 
body of an adult contains 15~20mg of iodine, of which 70~80% is in the thyroid gland.(Ahad 
and Ganie 2010) To produce a normal quantity of thyroid hormone, about 50 mg of ingested 
iodine in the form of iodides are required each year. Oceans are the world’s main 
repositories of iodine and very little iodine is found in the soil.(Ahad and Ganie 2010) The 
major dietary sources of iodine are bread and milk in the US and Europe, but the main 
source is seaweed in some Asian countries.(Zimmermann and Crill; Ahad and Ganie 2010; 
Hall 2011) Iodine is found in various forms in nature such as inorganic sodium or potassium 
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salts (sodium iodide or potassium iodide), inorganic diatomic iodine or organic monoatomic 
iodine. (Ahad and Ganie 2010) Iodide, represented by I − , is the ion of iodine and it 
combines with another element or elements to form a compound. Although the iodine 
content of iodised salt may vary from country to country, common table salt has a small 
portion of sodium iodide to prevent iodine deficiency.(Hall 2011)  
 
Fig. 2. Cellular mechanism for iodine uptake in thyroid follicular cells. This commences with 
the uptake of iodide from the capillary into the follicular cell of the thyroid gland. This 
process occurs against chemical and electrical gradients via the sodium iodide symporter 
(NIS) located in the basal membrane of the follicular cell. Increased intracellular sodium is 
pumped out by the action of Na+/K+ ATPase. The iodide within the follicular cell moves 
towards the apical membrane to enter into the follicular lumen and then it is oxidized to 
iodine by peroxidase. Organification of the iodine follows the oxidation by iodination of the 
tyrosine residues present within the thyroglobulin (TG) molecule, and the iodine stays in the 
follicle before it is released into the circulation as thyroid hormones. Thyroid stimulating 
hormone (TSH) activates the follicular cell via TSH receptor (TSH-R) and increases the 
expression of the NIS and the TG. 
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2.1 Iodine absorption and metabolism 
Ingested iodides are rapidly and nearly completely absorbed (>90%) from the duodenum 
into the blood and most of the iodides are excreted by kidneys. Sodium iodide symporter 
(NIS) on the apical membrane of enterocytes mediates active iodide uptake. Normally about 
one fifth of absorbed iodides are taken up by thyroid follicular cells and this is used for 
thyroid hormone synthesis, yet the clearance of circulating iodide varies with iodine intake. 
In the condition of an adequate iodine supply, ≤10% of absorbed iodides are taken up by the 
thyroid and in chronic iodine deficiency, this fraction can exceed 80%.(Zimmermann and Crill) 
The basal membrane of the thyroid follicular cell is able to actively transport iodide to the 
interior of the cell against a concentration gradient by the action of the NIS, which co-transports 
one iodide ion along with two sodium ions. The process of concentrating iodide in the thyroid 
follicular cells is called iodide trapping and presence of the NIS is essential for the process.(Hall 
2011) Thyroid hormones are produced by oxidation, organification and coupling processes in 
the thyroid gland and they are finally released into the blood stream for their action.   
2.2 Sodium iodide symporter 
The rat NIS gene and the human NIS gene were cloned in 1996.(Dai, Levy et al. 1996; 
Smanik, Liu et al. 1996) NIS is a 13 transmembrane domain protein with an extracellular 
amino- and intracellular carboxyl-terminus and the expression of the NIS gene is mainly 
regulated by thyroid stimulating hormone (TSH). Binding of TSH to its receptor activates 
the NIS gene transcription and controls translocation and retention of NIS at the plasma 
membrane, and so this increases iodide uptake. 
In addition to its expression in the thyroid follicular cells, NIS is detectable and active in 
some extrathyroidal tissues such as the salivary glands, gastric mucosa, lactating mammary 
glands, etc. Therefore, these tissues are able to take up iodide by the action of the NIS. 
However, contrary to thyroid follicular cells, there are no long-term retention of iodide and 
TSH dependency. (Baril, Martin-Duque et al. 2010) The physiologic function of the NIS in 
the extrathyroidal tissues is not yet clear. 
3. Procedures for radioiodine whole body imaging 
3.1 Patients preparation 
Thyroid hormone replacement must be withheld for a sufficient time to permit an adequate 
rise of TSH (>30 uIU/mL). This is at least 2 weeks for triiodothyronine (T3) and 3–4 weeks 
for thyroxine (T4). This is also achieved by the administration of recombinant human TSH 
(rhTSH, Thyrogen®, given as two injections of 0.9 mg intramuscularly on each of two 
consecutive days) without stopping thyroid hormone replacement. rhTSH must be used in 
patients who may not have an elevation of TSH to the adequate level due to a large residual 
volume of functioning thyroid tissue or pituitary abnormalities, which precludes elevation 
of TSH. rhTSH might be used to prevent severe hypothyroidism related to the stopping of 
thyroid hormone replacement.(Silberstein, Alavi et al. 2005; Silberstein, Alavi et al. 2006)  
All patients must discontinue eating/using iodide-containing foods or preparations, and other 
medications that could potentially affect the ability of thyroid cancer tissue to accumulate 
iodide for a sufficient time before radioiodine administration. A low-iodine diet is followed for 
7–14 days before the radioiodine is given, as it significantly increases the uptake of radioiodine 
by the well differentiated thyroid cancer tissue. The avoided or permitted food items are 
summarized in table 1. The recommended time interval of drug withdrawal is summarized in 
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table 2. Imaging should be delayed for a long enough period to eliminate the effects of these 
interfering factors. The goal of a low iodine diet and the drug withdrawal is to make a 24-hour 
urine iodine output of about 50 ug.(Silberstein, Alavi et al. 2006). 
 
 Allowed Not-allowed 
Salts Non -iodized salt  
Iodized salt 
Sea salt 
Fruits and 
vegetables 
Fresh fruits and juices 
Rhubarb 
Fruit or juice with red dye # 3 
Canned or preserved 
Seafood and 
sea products 
None 
Fish 
Shellfishs 
Seaweeds 
Seaweed tableets 
Agar-agar 
Dairy 
products 
None 
Milk  
Cheese 
Yogurt 
Butter 
Ice cream 
Chocholate (has milk content) 
Paultries and 
Meats 
Fresh unsalted  Canned and processed 
Egg 
Whites of eggs  
 
Egg yolks 
Whole eggs 
Grain 
products 
breads, cereal and crackers without salt 
unsalted pasta, rice, rice cakes, and 
popcorn 
Breads, cereals or crackers made 
with salt 
Salted pasta, rice or popcorn 
drinks 
Cola, diet cola, lemonade  
Coffee or tea without milk or cream 
Fruit juice without red dye#3 
Fruit smoothies made without dairy or 
soy products 
Beer, wine and spirits 
Milk, cream or drinks made with 
dairy 
Fruit juice and soft drinks with 
red dye#3 
Table 1. Food guide for a low iodine diet. Some items on the allowed list may not be low in 
iodine in some forms or merchandise brands. The labels must be checked to be sure that the 
items meet the requirements of the low-iodine diet. (Amin, Junco et al.; Nostrand, Bloom et 
al. 2004) 
3.2 Types of radioiodine 
3.2.1 I-131  
I-131 is produced in a nuclear reactor by neutron bombardment of natural tellurium (Te-127) 
and decays by beta emission with a half-life of 8.02 days to xenon-133 (Xe-133) and it emits 
gamma emission as well. It most often (89% of the time) expends its 971 keV of decay energy 
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by transforming into the stable Xe-131 in two steps, with gamma decay following rapidly 
after beta decay. The primary emissions of I-131 decay are beta particles with a maximal 
energy of 606 keV (89% abundance, others 248–807 keV) and 364 keV gamma rays (81% 
abundance, others 723 keV). 
I-131 is administered orally with activities of 1–5 mCi or less, with many preferring a range 
of 1–2 mCi because of the data suggesting that stunning (decreased uptake of the therapy 
dose of I-131 by the residual functioning thyroid tissue or tumour due to cell death or 
dysfunction caused by the activity administered for diagnostic imaging) is less likely at the 
lower activity range. However, detection of more iodine concentrating tissue has been 
reported with higher dosages.(Silberstein, Alavi et al. 2006) 
 
Type of medication Recommended time interval of withdrawal 
Natural synthetic thyroid hormone 
    Thyroxine (T4) 
    Triiodothyroinine (T3) 
 
3 to 4 weeks 
10 to 14 days 
Amiodarone 3 to 6 months 
Multivitamine 6 weeks 
Lugol’s solution, potassium iodide solution 
(SSKI) 
6 weeks  
Topical iodine  6 weeks 
Radiographic contrast agents 3 to 6 months, depending on iodide content  
Iodinated eyedrops and antiseptics 6 weeks 
Iodine containing expectorants and anti-
tussives 
2 to 4 weeks 
Table 2. Recommended time intervals of withdrawal for drugs affecting radioiodine uptake. 
The time interval can be changed by the administered doses of the medications. The amount 
of iodine for the drug must also be considered.(Nostrand, Bloom et al. 2004; Silberstein, 
Alavi et al. 2005; Luster, Clarke et al. 2008)  
3.2.2 I-123 
I-123 is produced in a cyclotron by proton irradiation of enriched Xe-124 in a capsule and  
I-123 decays by electron capture with a half-life of 13.22 hours to Te-123 and it emits gamma 
radiation with predominant energies of 159 keV (the gamma ray primarily used for 
imaging) and 127 keV.  
I-123 is mainly a gamma emitter with a high counting rate compared with I-131, and I-123 
provides a higher lesion-to-background signal, thereby improving the sensitivity and imaging 
quality. Moreover, with the same administered activity, I-123 delivers an absorbed radiation 
dose that is approximately one-fifth that of I-131 to the thyroid tissue, thereby lessening the 
likelihood of stunning from imaging. I-123 is administered orally with activities of 0.4–5.0 mCi, 
which may avoid stunning.(Ma, Kuang et al. 2005; Silberstein, Alavi et al. 2006) 
3.2.3 I-124 
I-124 is a proton-rich isotope of iodine produced in a cyclotron by numerous nuclear 
reactions and it decays to Te-124 with a half-life of 4.18 days. Its modes of decay are: 74.4% 
www.intechopen.com
 Physiologic and False Positive Pathologic Uptakes on Radioiodine Whole Body Scan 
 
7 
electron capture and 25.6% positron emission. It emits gamma radiation with energies of 511 
and 602 keV.(Rault, Vandenberghe et al. 2007)  
I-124 is administered intravenously with activities of 0.5–2.0 mCi for detection of metastatic 
lesions or assessment of the radiation dose related to I-131 therapy. 
 
Types Advantages Disadvantages 
I-131 
• Cheap 
• Readily available 
• Allows longer delayed image 
• Potential stunning 
• Requirement of possible radiation 
safety precautions for family and 
caregivers 
I-123 
• No stunning 
• Good image quality 
• Limited availablity 
• Expensive 
I-124 
• Superior image quality 
• Tomographic image 
• Allows intermediate delayed 
image 
• Fusion image with CT or MR 
• Very limited availability 
• Very expensive 
Table 3. Advantages and disadvantages according to the types of radioiodine.(Nostrand, 
Bloom et al. 2004) 
3.3 Planar, SPECT and PET imaging 
3.3.1 Planar imaging 
Planar gamma camera imaging can be obtained with gamma emitting I-123 or I-131 for the 
detection of thyroid cancer tissue expressing the NIS gene which takes up iodine. The main 
emission energy peak of I-131 is approximately 364 keV, so it requires the use of a high-energy 
all-purpose collimator for imaging acquisition. The peak of the I-123 is 159 keV, which is close 
to the 140 keV from Tc-99m for which the gamma camera’s design has traditionally been 
optimized. I-123 can be imaged with a low-energy high-resolution collimator, which is 
optimized for image acquisition with Tc-99m. (Rault, Vandenberghe et al. 2007) 
With radioiodine’s avidity for differentiated thyroid cancer tissues, planar radioiodine 
whole body image has been mainly used for the detection of metastatic thyroid cancer 
lesions. However, the limited resolution of planar imaging together with the background 
activity in the radioiodine images can give false-negative results for small lesions. 
Physiologic uptake of radioiodine is not always easily differentiable from pathologic uptake 
and it can give false-positive results. (Spanu, Solinas et al. 2009) Therefore, the sensitivity 
and specificity of planar images for the diagnosis of metastatic thyroid cancer may be 
limited. (Oh, Byun et al. 2011) 
3.3.2 SPECT (Single Photon Emission Computed Tomography) or SPECT/CT imaging 
Although a radioiodine whole body scan is one of the excellent imaging tools for the 
detection of thyroid cancer, false negative results may be observed in cases with small 
recurrent lesions in an area of rather high background activity or in cases with poorly 
differentiated cancer tissues, which have low uptake ability for radioiodine (due to 
dedifferentiation).(Geerlings, van Zuijlen et al.) SPECT, which can provide cross-sectional 
scintigraphic images, has been proposed as a way to overcome the limitations of planar 
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imaging and it is known to have higher sensitivity and better contrast resolution than planar 
imaging. Radioiodine SPECT has higher performance for detecting recurrent lesion 
compared to planar imaging in thyroidectomized thyroid cancer patients and it also changes 
the patients’ management. 
Radioiodine SPECT has excellent capability to detect thyroid cancer tissues, yet the anatomic 
evaluation of lesion sites with radioiodine uptake remains difficult due to the minimal 
background uptake of the radioiodine. The performance of SPECT with radioiodine may be 
further improved by fusing the SPECT and CT images or by using an integrated SPECT/CT 
system that permits simultaneous anatomic mapping and functional imaging.(Geerlings, van 
Zuijlen et al.; Spanu, Solinas et al. 2009) The fusion imaging modality can synergistically and 
significantly improve the diagnostic process and its outcome when compared to a single 
diagnostic technique. (Von Schulthess and Hany 2008) Therefore, SPECT/CT with radioiodine 
can demonstrate a higher number of radioiodine uptake lesions, and it can more correctly 
differentiate between physiologic and pathologic uptakes, and so it permits a more 
appropriate therapeutic approach to be chosen.(Spanu, Solinas et al. 2009) Despite its many 
advantages, SPECT/CT cannot be applied for routine use or whole body imaging due to the 
long scanning time and the additional radiation burden, and so the fusion image should be 
selected on a personalized basis for those who clinically need the imaging. (Oh, Byun et al. 2011) 
3.3.3 PET (Positron Emission Tomography) or PET/CT imaging 
PET detects a pair of gamma rays produced by annihilation of a positron which is 
introduced by a positron emitting radionuclide and this produces three-dimensional image. 
Owing to its electronic collimation, I-124 PET gives better efficiency and resolution than in I-
123 or I-131 SPECT, and so it offers the best image quality. (Rault, Vandenberghe et al. 2007)  
A fusion imaging modality with I-124 PET and CT can improve the diagnostic efficacy when 
compared to I-124 PET imaging by the same reasons of SPECT/CT over SEPCT only. I-124 
PET/CT has superiority due to the better spatial resolution and faster imaging speed 
compared to I-123 or I-131 SPECT/CT.(Van Nostrand, Moreau et al. 2010) PET fused with 
MR is recently being used for research and in clinic fields and it will allow state of art 
imaging in the near future. 
4. Physiologic radioiodine uptake 
Following thyroid ablation, physiologic activity is expected in the salivary glands, stomach, 
breast, oropharynx, nasopharynx, oesophagus, gastrointestinal tract and genitourinary 
tract.(Ozguven, Ilgan et al. 2004) Physiologic radioiodine accumulation is related to the 
expression of the NIS and metabolism related to or the retention of excreted iodine. (Bakheet, 
Hammami et al. 2000; Ahn, Lee et al. 2011) Uptake of radioiodine in the thyroid tissue, salivary 
gland, stomach, lacrimal sac, nasolacrimal duct and choroid plexus is related to the NIS 
expression of the cells of the organs.(Morgenstern, Vadysirisack et al. 2005) Ectopic thyroid 
tissues are found by a variety of embryological maldevelopments of the thyroid gland such as 
lingual or sublingual thyroid (by failure of migration), a thyroglossal duct (by functioning 
thyroid tissue in the migration route) and a mediastinal thyroid gland (by excessive 
migration). Other abnormal migration may produce widely divergent ectopic thyroid tissue in 
many organs such as liver, oesophagus, trachea, etc. In addition, normal thyroid tissue can be 
in the ovary (Struma ovarii. It can be classified as uptake in a pathologic lesion.). (Shapiro, 
Rufini et al. 2000) Ectopic gastric mucosa can be located in the small bowel (Meckel's 
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diverticulum) or terminal oesophagus (Barrett's oesophagus). (Ma, Kuang et al. 2005) The 
ectopic thyroid and gastric mucosal tissues are able to take up radioiodine.  
Uptake of iodine in the liver after radioiodine administration is related to the metabolism of 
radioiodinated thyroglobulin and thyroid hormones in the organ. The gall bladder also may 
occasionally be depicted with the biliary excretion of the radioiodine. (Shapiro, Rufini et al. 
2000; Carlisle, Lu et al. 2003) A simultaneous hepatobiliary scan with Tc-99m DISIDA 
(Diisopropyl Iminodiacetic Acid) or mebrofenin is useful for characterizing the gall bladder 
uptake. Tracer accumulation in the oropharynx, nasopharynx and oesophagus is related to 
retention of salivary excretion of administered radioiodine.  
Visualization of the oesophagus is extremely common and vertical linear uptake in the 
thorax that is removed by drinking water is characteristic of oesophageal uptake by 
swallowing of radioactive saliva. The oesophageal activity may also arise from gastric 
reflux. (Carlisle, Lu et al. 2003) Image acquisition after a drink of water is able to distinguish 
the activity from mediastinal node metastasis. (Shapiro, Rufini et al. 2000)  
Urinary or gastrointestinal anomalies can be responsible for false positive radioiodine uptake. 
(Ma, Kuang et al. 2005) Visualization of kidney and bladder after radioiodine administration is 
possible and this is known to be related to the urinary excretion of radioiodine into the urinary 
collecting system. Administered radioiodine is excreted mainly by the urinary system, and so 
all dilations, diverticuli and fistulae of the kidney, ureter and bladder may produce 
radioiodine retention.(Shapiro, Rufini et al. 2000) Visualizing the location of the renal pelvis of 
ectopic, horseshoe and transplanted kidneys is not usual and radioiodine at the pelvis may 
lead to misinterpretation. In fact, the renal pelvis and ureter are usually not visualized due to 
the rapid transit time of the radioiodine. (Bakheet, Hammami et al. 1996) A simultaneous renal 
scan with Tc-99m DTPA (Diethylene Triamine Pentaacetic Acid) or MAG3 (Mercapto Acetyl 
Triglycine) is useful for characterizing the urinary tract uptakes. (Shapiro, Rufini et al. 2000) 
Although the incidence is very uncommon, renal cysts are known to produce radioiodine 
uptake. The proposed mechanisms for the renal cyst uptake are a communication between the 
cyst and the urinary tract and radioiodine secretion by the lining epithelium of the cyst. 
(Shapiro, Rufini et al. 2000) 
Tracer accumulation in the colon is very common. Incomplete absorption of the oral 
radioiodine administration is not considered as the reason of colonic activity due to the lack 
of colonic activity seen on the early images. Tracer accumulation is probably due to 
transport of radioiodine into the intestine from the mesenteric circulation and biliary 
excretion of the metabolites of radioiodinated thyroglobulin. (Hays 1993) Appropriate use of 
laxatives can be a simple remedy for the activity. (Shapiro, Rufini et al. 2000) 
 
Fig. 3. Physiologic uptake of radioiodine in the nasal cavity, the so called "hot nose". Intense 
tracer uptake was noted at the thyroid bed area (due to residual thyroid tissue), breast and 
salivary gland (by the NIS expression of the glands).  
right lateral left lateralanterior
www.intechopen.com
 12 Chapters on Nuclear Medicine 
 
10
 
Fig. 4. Physiologic uptake of radioiodine in residual thyroid tissue. Intense tracer uptake 
was noted at the thyroid bed area due to residual thyroid tissue.  
Lactating mammary glands express the NIS, and so the lactating breast shows intense 
radioiodine uptake that might persist for months after cessation of lactation. Mild to 
moderate uptake is also seen in non-lactating breast tissue, which can be asymmetrical, 
presumably owing to the same mechanism that operates in lactation.(Shapiro, Rufini et al. 
2000; Tazebay, Wapnir et al. 2000)  
Uptake of radioiodine can occur in a residual normal thymus or in thymic hyperplasia and 
the suggested mechanisms for the uptake are the expression of the NIS in thymic tissues and 
the iodine concentration by the Hassal’s bodies that are present in the thymic tissue, which 
resemble the follicular cells of the thyroid. Thymic radioiodine uptake is more common in 
young patients compared to older patients. Even though the incidence is very rare, an 
intrathymic ectopic thyroid tissue or thyroid cancer metastases to the thymus can be a 
possible cause of uptake. (Mello, Flamini et al. 2009) 
 
 
Fig. 5. Physiologic uptake of radioiodine in residual thyroid tissue. Intense tracer uptake was 
noted at the midline of the upper neck due to residual thyroid tissue in the thyroglossal duct. 
Mild tracer uptake of the salivary gland (by the NIS expression of the glands) was also noted. 
right lateral left lateral 
anterior 
posterior 
right lateral left lateral
anterior
posterior
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Fig. 6. Physiologic uptake of radioiodine in both the parotid and submandibular salivary 
glands. Intense activity in the oral and nasal cavities (by saliva and nasal secretion) was also 
noted.  
 
 
Fig. 7. Physiologic uptake of radioiodine in the breast. Diffuse, moderate radioactivity in the 
breast was noted. There was also noted physiologic tracer uptake in the thyroid bed 
(suggesting remnant thyroid tissue, which has the NIS expression), salivary glands (by the 
NIS expression of the glands), stomach (by the NIS expression of the glands), bowel (by 
secretion of radioiodine into the intestine or biliary excretion of the metabolites of 
radioiodinated proteins) and urinary bladder (by urine activity). 
 
 
Fig. 8. Physiologic uptake of radioiodine in the breast. Intense tracer accumulation was 
noted in both breasts. Physiologic tracer uptake was also noted in the thyroid bed 
(suggesting remnant thyroid tissue, which has the NIS expression). 
anterior posterior 
anterior posterior 
anterior posterior
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Fig. 9. Physiologic uptake of radioiodine in the breast. Focal tracer uptake in the breast was 
noted. SPECT/CT revealed the accurate location of the breast uptake. Physiologic intense 
tracer uptake was noted in the thyroid bed (suggesting remnant thyroid tissue, which has 
the NIS expression) and mild tracer uptake in the liver (by metabolism of radioiodinated 
thyroglobulin and thyroid hormones). 
 
 
Fig. 10. Physiologic uptake of radioiodine in the oesophagus. Vertical linear radioactivity in 
the chest was noted by stagnation of swallowed saliva containing radioiodine. There was 
also noted physiologic tracer uptake in the thyroid bed area (by residual thyroid tissue) and 
salivary glands (by the NIS expression of the glands).  
 
 
Fig. 11. Physiologic uptake of radioiodine in the gall bladder. Intense tracer accumulation 
was noted at the GB fossa area on the whole body scan and SPECT/CT revealed accurate 
localization of the uptake. There was also noted physiologic tracer uptake in the thyroid bed 
area by residual thyroid tissue. 
anterior CT 
anterior posterior 
anterior posterior 
CT 
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Fig. 12. Physiologic uptake of radioiodine in the thymus. Diffuse, mild radioactivity in the 
mid-thorax was noted. There was also noted physiologic tracer uptake in the salivary glands 
(by the NIS expression of the glands) and oral cavity (by saliva containing radioiodine). 
 
 
Fig. 13. Physiologic uptake of radioiodine in the stomach. Intense tracer uptake was noted at 
the left upper quadrant of abdomen due to stomach uptake of the tracer. There was also 
noted tracer uptake in the oral cavity (radioactivity of secreted saliva), salivary gland (by the 
NIS expression of the glands), thyroid bed (suggesting remnant thyroid tissue, which has 
the NIS expression) and urinary bladder (by urine activity). 
 
 
Fig. 14. Focal radioiodine uptake was noted at the center of the abdomen. The uptake might 
be related to ectopic gastric mucosa in the Meckel’s diverticulum. There was also noted 
tracer uptake in the stomach (by the NIS expression of the gastric mucosa), oral cavity 
(radioactivity of the secreted saliva) and salivary gland (by the NIS expression of the glands).   
right lateral left lateralanterior 
anterior posterior 
anterior posterior
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Fig. 15. Physiologic uptake of radioiodine in the lacrimal sac. The uptake is known to be 
related to active iodine transport by the NIS at the lining epithelium of the sac. There was 
also noted intense tracer accumulation in the thyroid bed (by remnant tissue of the thyroid, 
which has the NIS expression) and oral cavity (by the radioactivity of secreted saliva) and 
minimal tracer uptake in the salivary glands (by the NIS expression of the glands). 
 
 
Fig. 16. Physiologic uptake of radioiodine in the liver. The uptake is known to be related to 
metabolism of radioiodinated thyroglobulin and thyroid hormones in the liver. There was 
also noted intense tracer accumulation in the thyroid bed (by the remnant tissue of the 
thyroid). 
 
 
Fig. 17. Physiologic uptake of radioiodine in the urinary bladder. Intense tracer uptake was 
noted at the suprapubic area by radioactive urine in the bladder. Tracer uptake was noted in 
the salivary glands (by the NIS expression of the glands) and perineal area (due to urine 
contamination). 
anterior 
posterior 
right lateral left lateral 
anterior posterior 
anterior posterior
www.intechopen.com
 Physiologic and False Positive Pathologic Uptakes on Radioiodine Whole Body Scan 
 
15 
  
Fig. 18. Physiologic uptake of radioiodine in a simple cyst of the right kidney. Focal tracer 
uptake was noted at the right side abdomen. The proposed mechanisms are communication 
between the cyst and the urinary tract and radioiodine secretion by the lining epithelium of 
the cyst. There was intense tracer uptake noted in the thyroid bed area (by the remnant 
tissue of the gland) and mild tracer uptake in the salivary gland (by the NIS expression of 
the glands). 
 
             
          (A)                                (B) 
Fig. 19. Physiologic uptake of radioiodine in the colon. Intense tracer uptake was noted at 
the colon. The suggested mechanisms for the uptake are transportation of radioiodine into 
the intestine from the mesenteric circulation and biliary excretion of the metabolites of 
radioiodinated thyroglobulin or thyroid hormones. There was also noted tracer uptake in 
(A) the oral cavity (by the radioactivity of secreted saliva), (B) the salivary glands (by the 
NIS expression of the glands) and stomach (by the NIS expression of the gastric mucosa).   
5. Pathologic lesions might show false positive radioiodine uptake 
A variety of pathologic lesions producing a false positive radioiodine whole body scan have 
been reported and contrary to the physiologic uptakes that usually do not create diagnostic 
confusion, they might be tricky enough to cause some patients to undergo unnecessary 
fruitless invasive surgical or high dose radioiodine treatment.(Mitchell, Pratt et al. 2000)  
The not uncommon pathologic lesions showing radioiodine uptake are cystic, inflammatory, 
non-thyroidal neoplastic diseases. Cystic lesions in various organs can accumulate 
radioiodine and the mechanism of the uptake is passive diffusion of the tracer into the cysts. 
Radioiodine accumulation in ovarian, breast and pleuropericardial cysts has been reported. 
anterior CT
right lateral left lateral
anterior posterior anterior posterior 
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(Shapiro, Rufini et al. 2000) Effusion of the pleural, pericardial and peritoneal cavities can 
also have radioiodine uptake by the same mechanism.(Shapiro, Rufini et al. 2000)  
A variety of inflammatory and infectious disease can have radioiodine accumulation by 
increased blood flow that delivers increased levels of radioiodine to the site, and enhanced 
permeability of the capillary that increases diffusion of the tracer to the extracellular water 
space.(Shapiro, Rufini et al. 2000) Radioiodine accumulation in bronchiectasis, pulmonary 
aspergilloma, skin wound, arthritis, paranasal sinusitis, skin infection, myocardial infarction 
and dacryocystitis has been reported.(Shapiro, Rufini et al. 2000; Ahn, Lee et al. 2011)  
Even though only a minority of such lesions accumulate the tracer, a variety of non-
thyroidal neoplasms are also known to take up radioiodine. The suggested mechanisms are 
i) a tumour expression of the NIS, which actively accumulates the tracer and ii) increased 
vascularity and enhanced capillary permeability that might be secondary to the 
inflammatory response associated with the neoplasm.(Mitchell, Pratt et al. 2000; Shapiro, 
Rufini et al. 2000) Radioiodine accumulation in breast cancer, gastric adenocarcinoma, 
bronchial adenocarcinoma, bronchial squamous carcinoma, salivary adenocarcinoma, 
teratoma, ovarian adenocarcinoma and meningioma has been reported.(Shapiro, Rufini et 
al. 2000)  
Fortunately, false positive uptake on a radioiodine whole body scan can be interpreted with 
using the serum thyroglobulin value, which is very sensitive marker for residual or 
recurrent thyroid cancer. Therefore, the false positive uptake usually does not cause a 
diagnostic dilemma for experienced practitioners. The clinical features and other imaging 
studies can also help to distinguish the false positive pathologic lesions from true positive 
metastatic thyroid cancer lesions.(Mitchell, Pratt et al. 2000; Ahn, Lee et al. 2011) 
 
 
 
 
Fig. 20. Pathologic uptake of radioiodine in the bronchectatic lesions of both lungs. There 
was also noted intense tracer uptake in the thyroid bed area (by the remnant tissue of the 
gland). 
anterior 
CT 
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Fig. 21. Pathologic uptake of radioiodine in a pulmonary fungus ball. There was also noted 
tracer uptake in the thyroid bed area (by the remnant tissue of the gland) and the liver (by 
metabolism of the radioiodinated thyroglobulin and thyroid hormones). 
 
 
Fig. 22. Pathologic uptake of radioiodine in a skin wound. There was tracer uptake in the left 
lower leg where the skin wound was located. There was tracer uptake in the salivary gland 
(by the NIS expression of the glands), thyroid bed (by the remnant tissue of the gland) and 
the liver (by metabolism of the radioiodinated thyroglobulin and thyroid hormones). 
6. Contaminations by physiological secretions 
External contamination by physiological or pathological body secretions or excretions can 
cause positive radioiodine uptake and this mimics metastatic involvement of differentiated 
thyroid cancer.(Bakheet, Hammami et al. 2000) Sweat, breast milk, urine, vomitus and nasal, 
tracheobronchial, lacrimal, salivary secretions and faeces contain radioiodine and their 
contamination on the hair, skin or clothes can be misinterpreted as metastasis of thyroid 
cancer.(Shapiro, Rufini et al. 2000) Any focus of radioiodine uptake that cannot be explained 
by physiological or pathological causation must also be suspected as arising from 
contamination by secretions. Fortunately, the contaminations are usually easily recognized by 
their pattern and acquiring images after removing the contamination with decontaminating 
procedures and with taking the stained clothes off. However, unusual patterns of 
contamination might occur and suspecting uptake lesions as contamination would be difficult. 
posterioranterior CT
anterior 
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Patients' peculiar physical characteristics or odd habits produce extraordinary 
contamination patterns. Uptake in the scalp or a wig has been reported in patient with 
excessive sweating, and contamination of a wig was reported in patient with a bizarre habit 
of styling hair with sputum.(Bakheet, Hammami et al. 2000) False positive scans due to 
contamination can be kept to a minimum by careful preparation of patients, such as image 
acquisition in a clean gown after taking a shower. 
Contaminations are almost always superficial, (Carlisle, Lu et al. 2003), therefore, the use of 
lateral and/or oblique views to give a third dimension to the scan may help to identify the 
contamination. Furthermore, the SPECT image alone or the SPECT image fused with the 
anatomical image, which provides detailed information about the anatomic location of the 
radiotracer uptake sites, can be the best way to correctly determine that contamination is the 
reason for the uptakes.  
 
 
Fig. 23. Cases with contaminations at the hair and scalp. A case with unilateral hair 
contamination by saliva and cases with uni- or bilateral scalp contamination by excessive 
perspiration are demonstrated. 
 
 
 
Fig. 24. Contamination at the right posterior chest wall by excessive perspiration. There was 
also noted intense tracer accumulation in the thyroid bed (by remnant tissue of the thyroid 
and edema of the cervical soft tissue). 
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Fig. 25. Contamination at the skin of the right upper arm. There was also noted intense 
tracer accumulation in the rectum and moderate tracer accumulation in the descending 
colon and the liver. 
 
 
Fig. 26. Vanishing contaminations after cleansing the right forearm, both thighs and right 
foot. There was also noted intense tracer accumulation in the thyroid bed area and colon 
and moderate tracer accumulation in the liver. 
 
 Sites of uptake Mechamism of radioiodine uptake 
Physiologic 
Residual thyroid tissue thyroid bed 
Active radioiodine uptake by 
expression of the NIS 
Ectopic normal thyroid 
tissues 
Lingual thyroid  
mediatinal thyroid 
Intratracheal thyroid 
Paracardiac thyroid  
Intraheaptic thyroid
Active radioiodine uptake by the 
expression of the NIS 
Salivary gland 
Parotid and submandibular salivary 
glands 
Active radioiodine uptake by the 
expression of the NIS 
Lacrimal 
sac/nasolacrimal duct 
Lacrimal gland* 
Ocular and periocular area 
Active radioiodine uptake by the 
expression of the NIS 
*controversial 
anterior posterior 
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 Sites of uptake Mechamism of radioiodine uptake 
By excreted or 
swallowed saiva 
Oral cavity 
Oesophagus 
Oesophageal diverticulum 
Oesophageal stricture or scarring 
Achalasia 
Focal accumulated saliva with 
radioiodine activity from the salivary 
glands  
By nasal secretion Nose "hot nose" 
Focal accumulated nasal secretion 
with radioiodine 
By excreted urine 
Renal pelvis 
Ureter 
Urinary bladder 
Urinary tract diverticulum 
Urinary tract fistula 
Renal cyst* 
Accumulated urine radioiodine 
activity excreted by the kidneys 
* Active radioiodine uptake by the 
expression of the NIS can be another 
mechanism 
Choroid plexus Brain 
Active radioiodine uptake by the 
expression of the NIS 
Thymic uptake Thymus 
Expression of the NIS in thymic 
tissues and/or iodine concentration by 
Hassal’s bodies 
Gastric mucosa 
Stomach 
Gastric duplication cyst 
Meckel‘s diverticulum 
Barrett esophagus 
Active radioiodine uptake by the 
expression of the NIS 
By excreted gastric 
secretion 
Oesophageal uptake 
Bowel uptake 
Gastroesophagel reflux 
Translocation of excreted gastric 
secretion into the bowel 
Metabolism of 
radioiodinated proteins
Liver 
Biliary tract 
Gall bladder 
Bowels 
Metabolism of radioiodinated thyroid 
hormones or thyroglobulin and their 
excretion into the gall bladder and 
bowels via the biliary tract 
Breast Breast, especially lactating 
Active radioiodine uptake by the 
expression of the NIS 
Colon 
Diffuse and/or focal (any part of 
colon) 
Transport of radioiodine into the 
intestine from the mesenteric 
circulation and biliary excretion of the 
metabolites of radioiodinated 
thyroglobulin. 
Pathologic 
Heterotopic thyroid 
tissue 
Struma ovarii 
Active radioiodine uptake by the 
expression of the NIS 
Inflammations 
associated with/without 
infection 
Pericarditis 
Skin burn 
Dental disease 
Arthritis 
Cholecystitis 
Folliculitis  
Paranasal sinusitis 
Dacryocystitis 
Bronchiectasis 
Fungal infection (eg, aspergilloma) 
Increased perfusion and vasodilation, 
and enhanced capillary permeability 
by the inflammation 
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 Sites of uptake Mechamism of radioiodine uptake 
Pleural and pericardial effusions 
Non-thyroidal neoplasm
Gastric adenocarcinoma 
Salivary adenocarcinoma 
Lung adenocarcinoma 
Fibroadenoma  
Meningioma 
Nurilemoma 
Teratoma
Active radioiodine uptake by the NIS 
of the tumor and/or incresed blood 
flow and enhanced capillary 
permeability in the tumor 
Trauma 
Biopsy site 
Tracheostomy site 
Increased perfusion and vasodilation, 
and enhanced capillary permeability 
by the tissue trauma 
Contaminations 
Tear 
Skin of any part of the body, hair, 
wig, cloth, etc 
Contamination by physiological or 
pathological body secretions or 
excretions 
Saliva 
Sweat 
Vomitus 
Breast milk 
Urine 
Feces 
Table 4. Causes of radioiodine uptake not related to thyroid cancer on the radioiodine whole 
body scan.   
 
 
Fig. 27. Schematic presentation for the locations of physiologic uptake and possible 
contamination sources the radioiodine whole body scans. 
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7. Conclusion 
A whole body scan obtained with the administration of a diagnostic or therapeutic dose of 
radioiodine has a definite role in the management of patients with well differentiated 
thyroid cancer after total thyroidectomy. Accurate interpretation of the scan requires a 
thorough knowledge and understanding of potential confounding factors for uptakes on the 
scan, and recognition of the variable causes of false positive uptake will provide correct 
prognostic inferences and prevent inappropriate therapeutic interventions. In addition, the 
cause of radioiodine uptake on the scan is always evaluated in conjunction with the serum 
thyroglobulin level and the clinico-radiological results in order to lessen the chance of an 
incorrect conclusion about the uptakes. 
This chapter was written to make readers consider a broad variety of diseases as the causes 
of the uptake on the radioiodine whole body scan and I have demonstrated a wide variety 
of causes of false positive uptakes on these scans.  
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